Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05584202 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
A Phase 2 study, sponsored by ModernaTX.
- Terminated
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT05584202 is a Phase 2 study that was terminated before completion, run by ModernaTX. The registered enrollment target is 68 participants.
The verdict
NCT05584202, a Phase 2 study, was terminated before completion, sponsored by ModernaTX.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1273.214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05584202
The ClinicalTrials.gov registry entry for NCT05584202 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05584202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05584202 about?
NCT05584202 is a clinical study titled "Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants". The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.
What is the current status of trial NCT05584202?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-09-30. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT05584202?
The interventions under investigation include: Placebo (OTHER), mRNA-1273.214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05584202?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.